Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.45 |
| ▸ | NAMPT | P43490 | 3/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.38 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30981400 | 0.93 | CYP11B2 (0.41) | GPR119NAMPTNR1H2CACNA2D1CACNA1B | |
| SCHEMBL27142937 | 0.91 | GPR119 (0.49) | GPR119NAMPTNR1H2DDB1CRBN | |
| SCHEMBL24950413 | 0.91 | ACACB (0.39) | GPR119NAMPTNR1H2DDB1CRBN | |
| SCHEMBL25229992 | 0.91 | GPR119 (0.42) | GPR119NAMPTNR1H2DDB1CRBN | |
| SCHEMBL30981206 | 0.89 | ACACB (0.40) | GPR119NR1H2 | |
| SCHEMBL2386299 | 0.88 | CACNA2D1 (0.47) | NR1H2DDB1CRBNHPGDUSP2 | |
| SCHEMBL27162617 | 0.87 | CYP2D6 (0.41) | GPR119HPGDCYP2D6USP2 | |
| SCHEMBL25572005 | 0.87 | HPGD (0.41) | GPR119NR1H2DDB1CRBNHPGD | |
| SCHEMBL27123600 | 0.86 | GPR119 (0.44) | GPR119NR1H2DDB1CRBNHPGD | |
| SCHEMBL27141632 | 0.86 | GPR119 (0.51) | GPR119NAMPTNR1H2DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094954-A | Tricyclic quinolones and 1, 8-naphthyridin-2-one BCL6 difunctional degrading agents | — | 2026-05-26 | — | — | CN | disclosed |
| US-20250276981-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. | 2025-09-04 | — | — | US | disclosed |
| US-20250270191-A1 | QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. | 2025-08-28 | — | — | US | disclosed |
| EP-4536650-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-4536658-A1 | 1,8-NAPHTHYRIDIN-2-ONE HETEROBIFUNCTIONAL BCL6 DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-4536649-A1 | QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| WO-2025050016-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-03-06 | — | — | WO | disclosed |
| WO-2025049968-A1 | TRICYCLIC QUINOLONE AND 1,8-NAPHTHYRIDIN-2-ONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-03-06 | — | — | WO | disclosed |
| WO-2025049964-A1 | BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-03-06 | — | — | WO | disclosed |
| CN-119317623-A | Tricyclic quinolone BCL6 bifunctional degradation agents | 树线生物科学公司 | 2025-01-14 | — | — | CN | disclosed |
| EP-4332100-A1 | PHOSPHONYL DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL APPLICATION THEREOF | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2024-03-06 | — | — | EP | disclosed |
| EP-4328219-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) | 2024-02-28 | — | — | EP | disclosed |
| EP-4328219-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) | 2024-02-28 | — | — | EP | disclosed |
| CN-117425646-A | Phosphono derivative, composition thereof and pharmaceutical application thereof | 西藏海思科制药有限公司 | 2024-01-19 | — | — | CN | disclosed |
| WO-2023244917-A1 | 1,8-NAPHTHYRIDIN-2-ONE HETEROBIFUNCTIONAL BCL6 DEGRADERS | Treeline Biosciences, Inc. (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023244918-A1 | QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023240038-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2022228547-A1 | PHOSPHONYL DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL APPLICATION THEREOF | 四川海思科制药有限公司 | 2022-11-03 | — | — | WO | disclosed |
| WO-2022223033-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海领泰生物医药科技有限公司 | 2022-10-27 | — | — | WO | disclosed |
| CN-115232111-A | SOS1 degradation agent and preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2022-10-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250276981-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | BCL6, BCL6B, BCOR | GPR119 3864/4885NAMPT 3709/4885NR1H2 2653/4885 |
| US-20250270191-A1 | QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | BCL6, BCL6B, BCOR | GPR119 3577/4885NAMPT 3608/4885NR1H2 2066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.